Senseonics (NYSE:SENS) said today that it launched the Eversense Bridge Program, which is designed to improve patient access to Senseonics’ Eversense continuous glucose monitoring system.
The company said that the program can help users confirm their insurance benefits and obtain pre-authorization before sensor placement. The Eversense Bridge Program is also meant to help healthcare providers and patients appeal to insurers regarding denied claims.
Get the full story at our sister site, Drug Delivery Business News.
The post Senseonics touts patient access program for Eversense CGM appeared first on MassDevice.
from MassDevice https://ift.tt/2TmoDqp
Cap comentari:
Publica un comentari a l'entrada